Citizens JMP reiterates market outperform rating on CRISPR stock

Investing.com - Citizens JMP analyst reiterated a Market Outperform rating and $86.00 price target on CRISPR Therapeutics (NASDAQ:CRSP) on Monday. The stock, currently trading at $46.70, has shown strong momentum with a 16.7% gain over the past six months. According to InvestingPro data, analyst targets for the stock range from $32 to $268, reflecting diverse views on the company’s potential.

The firm pointed to the recent transaction between Verve Therapeutics and Eli Lilly (NYSE:LLY) as evidence of growing big pharma interest in in-vivo gene editing for large indications, which it considers relevant to CRISPR’s prospects.

Citizens JMP noted that CRISPR Therapeutics is "currently not getting much value for the in-vivo portion of its pipeline" despite what the firm sees as positive developments in the company’s CTX310 data.

The research firm expressed that while it "would have appreciated a look at Lp(a)" in the current data, it believes a larger dataset at multiple doses expected next year will provide more informative results.

This future data will be particularly valuable when compared to Novartis (SIX:NOVN)’ Phase 3 HORIZON data, which could potentially establish connections between Lp(a) levels and clinical outcomes, according to the firm.

In other recent news, CRISPR Therapeutics has been the focus of several analyst updates and strategic developments. The company reported additional results from its Phase 1 study of CTX310, an in vivo gene therapy targeting cardiovascular disease, showing significant reductions in triglycerides and LDL levels. CRISPR plans to present the full CTX310 data at a medical meeting in the second half of 2025. The timeline for the CTX320 program, targeting the Lp(a) gene, has been adjusted, with initial data now expected in the first half of 2026. This decision reflects strategic considerations based on the evolving treatment landscape for Lp(a).

Clear Street downgraded CRISPR Therapeutics from Buy to Hold, citing valuation concerns as the stock approached its $45 price target. Meanwhile, Goldman Sachs maintained its Neutral rating with a $47.00 price target, emphasizing consistent efficacy and safety results from the CTX310 trial. Brookline Capital Markets reiterated a Buy rating with a $268.00 price target, highlighting the potential of CRISPR’s platform in transforming cardiovascular disease treatment. Chardan Capital Markets also maintained a Buy rating, viewing Eli Lilly’s acquisition of Verve Therapeutics as a positive signal for gene editing therapies in the cardiovascular space.

Barclays (LON:BARC) maintained an Equalweight rating and a $42.00 price target, noting the company’s ongoing progress in its cardiovascular programs. CRISPR Therapeutics continues to advance its pipeline, including the preclinical CTX340 program targeting AGT for refractory hypertension. These developments underscore CRISPR Therapeutics’ growing presence in the cardiovascular treatment landscape.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.